Karo Pharma AB | Mutual Funds
Mutual Funds that own Karo Pharma AB
DFA Continental Small Company Series
654,633
0.4%
150,225
0.04%
01/31/2018
Länsförsäkringar Sverige Index
458,430
0.28%
458,430
0.11%
07/31/2018
412,415
0.25%
0
0.11%
07/31/2018
Nordea Indexfond Sverige
372,110
0.23%
120,191
0.11%
05/31/2018
Lyxor UCITS ETF MSCI Europe
296,049
0.18%
0
0.05%
09/05/2018
SPDR S&P World (ex-US) ETF
227,037
0.14%
878
0.03%
09/06/2018
SEB Sverige Indexfond
221,944
0.14%
-12,683
0.04%
12/31/2017
DFA International Core Equity Portfolio
217,804
0.13%
29,444
0%
04/30/2018
Swedbank Robur Mix Indexfond Sverige
174,720
0.11%
0
0.01%
07/31/2018
SEB Swedish Ethical Beta Fund
168,100
0.1%
168,100
0.05%
12/31/2017
| Address |
Nybrokajen 7
Stockholm AB 111 48
Sweden
|
|
Employees
|
- |
| Website |
http://www.karopharma.se |
| Updated |
07/08/2019 |
| Karo Pharma AB is a healthcare company, which engages in the research, development, and distribution of innovative drugs for key medical needs. It focuses on the project portfolio consists of RORgamma, Multiple Sclerosis and Cancer, and T268A Common Cold Spray. The company was founded in 1987 and is headquartered in Stockholm, Sweden. |
